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Abstract: Hepatocellular carcinoma (HCC) incidence is rising. This paper summarises the current
state of knowledge and recent discoveries in the cellular and physiological mechanisms leading to the
development of liver cancer, especially HCC, and liver metastases. After reviewing normal hepatic
cytoarchitecture and immunological characteristics, the paper addresses the pathophysiological
factors that cause liver damage and predispose to neoplasia. Particular attention is given to chronic
liver diseases, metabolic syndrome and the impact of altered gut microbiota, disrupted circadian
rhythm and psychological stress. Improved knowledge of the multifactorial aetiology of HCC
has important implications for the prevention and treatment of this cancer and of liver metastases
in general.
Keywords: hepatocellular carcinoma; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis;
hepatic stellate cells; myofibroblasts; VEGF; immunity; circadian homeostasis; cortisol
1. Introduction
Hepatocellular carcinoma (HCC) is an aggressive tumour of the liver. Among all cancers, HCC is
one of the fastest growing causes of death globally [1]. HCC is often diagnosed when it has reached an
advanced stage, so it is often impossible to offer treatment with curative intent. Generally, HCC arises
in a liver that is compromised due to chronic injury or inflammation subsequent to chronic infection
with hepatitis B virus or hepatitis C virus (HCV). Vaccination against hepatitis B virus has been shown
to reduce HCC incidence rates in children [2]. Eradication of HCV using new direct-acting antiviral
drugs reduces the risk of HCC in patients with chronic HCV infection [3]. However, it was shown
that, although after hepatitis B virus or HCV eradication the regression of fibrosis or even reversal of
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cirrhosis may occur, these patients might have a greater HCC risk compared to pre-cirrhotic patients,
and moreover, the coexistence of a metabolic syndrome (hepatic manifestation related to hypertension,
diabetes mellitus, obesity and dyslipidemia) further increases the risk for HCC development [4].
However, even after virus eradication, a large percentage of patients remain at risk of HCC, and
consequently, also in the presence of a sustained virologic response, the screening programs for liver
diseases are required to take this possible event into account. HCC can also develop in the context
of non-infectious chronic hepatopathies such as alcoholic liver disease, non-alcoholic steatohepatitis
and metabolic syndrome. The last subgroup of HCC, in particular, presents at an advanced stage,
with about 25% presenting with extra-hepatic metastasis [5], as surveillance is not performed in a
non-alcohol/cirrhotic liver. Thus, currently liver damage leading to F3 fibrosis, which is related to the
tumour size, is now recognised as the main condition that confers a HCC risk and worsens prognosis
irrespective of the aetiology [6].
When HCC develops in liver parenchyma, it is encircled by extracellular matrix, stromal cells,
and secreted proteins within an immunosuppressive tumour microenvironment (TME). The TME
is populated by immune cells that interact among themselves and with the tumour. The makeup
of the TME depends on the biological characteristics of the neoplastic cells and on the patient’s
pathophysiological conditions. The immune system’s role in promoting HCC development has long
been a focus of study [7–9]. Particular interest has been addressed to the dual role of transforming
growth factor beta (TGF-β) in regulating haematopoietic cells and promoting liver fibrosis [10].
Additionally, of interest is the role of cancer-associated fibroblasts (CAFs) in reducing the number and
functional differentiation of tumour-infiltrating T cells [11]. Besides reducing the immune response,
TGF-β and CAFs contribute to many neoplastic processes, including angiogenesis and tumour cell
proliferation, energy metabolism reprogramming and resistance to killing.
HCC recurs after primary liver resection with curative intent in about 70% of patients [12]. The
risk of recurrence in HCC is high because of the biological and morphological nature of the liver.
Recurrent disease includes both intrahepatic metastasis, which usually form within the first two
years of diagnosis, and de novo cancer that generally occurs later. The hepatic vascular anatomy
and immunological characteristics create a pro-neoplastic niche for metastasis, while the continuing
damage to the liver creates pro-neoplastic sites susceptible to secondary tumours.
This paper reviews the normal hepatic cytoarchitecture and immunological features, and then
discusses factors that, by causing liver damage, predispose to the development of HCC and liver
metastases. These factors include chronic liver disease, an altered gut microbiota composition, and
changes in the circadian rhythm.
2. Hepatic Cytoarchitecture and Main Cell Types
The main physiological functions of the liver are metabolism of nutrients absorbed by the
gastrointestinal tract and detoxification of dangerous molecules present in the circulation. These
functions are responsible for a delicate balance between immune tolerance and immune response,
and their correct functioning requires a normal cytoarchitecture of hepatic lobules (Figure 1). This
cytoarchitecture includes polarized hepatocyte and an intricate network of discontinuous capillaries
(sinusoids) and bile ducts. Important cell types in the lobule are Kupffer cells, which are specialised
macrophages that take up and destroy foreign material [13], and hepatic stellate cells (HSCs), which are
involved in the response to liver damage [14]. HSCs are found in the space of Disse, which separates
hepatocytes from sinusoids.
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Figure 1. Struct re l l s. Oxygenated bl od enters the lobules via a hepatic arteriole,
and then flows through the sinusoids and drains into a c tr l i the centrilobular region. Blo d
enriched in nutrients and antigens from the gastrointestinal system enters the lobules via the portal
vein. This blo d is filtered by Kupffer cells, which are phagocytic cells found within and below the
fenestrated sinusoidal endothelium. Hepatic s ellate cells (fat-storing cells that secrete matrix proteins)
and antigen-presenting dendri c cells are pres nt in the space of Disse, which separates hepatocytes
(epithelial liver cells) from endothelial cells. Biliary canaliculi are located between the two cords
of hepatocytes.
The vascular endothelial growth factor (VEGF) signalling pathway regulates vascular
morphogenesis, which is important for both hepatic cytoarchitecture and cancer growth. The
concentration of VEGF determines the directionality of the angiogenic sprouting, and vessel extension
and growth (reviewed in [15]). VEGF expression is induced by hypoxia, a condition frequently found in
large tumours and associated with tumour growth. Upregulation of VEGF increases vasodilatation and
blood flow and hence oxygen availability within a tumour [16]. Because VEGF is the major cytokine
produced by activated HSCs, these cells are involved in maintenance of the sinusoidal endothelial cell
network. HSCs control endothelial characteristics such as fenestration and permeability and regulate
platelet–endothelial cell adhesion. These functions maintain the integrity of the endothelium and
speed the restoration of vascular permeability after inflammatory damage [17].
HSCs are also the main cell type involved in liver fibrosis, the formation of thickened, scarred
connective tissue subsequent to liver damage. Activated HSCs sustained by a profibrogenic
environment differentiate into collagen-producing myofibroblasts. These cells become detectable in
the liver during liver injury. They produce an abundant extracellular matrix that initially accumulates
in the space of Disse [18].
Another important cell is the Kupffer cell, a self-renewing macrophage that, like the myofibroblast,
accumulates in injured liver tissue. Kupffer cells recognise and clear pathogenic microbes and dying or
dead host cells that arrive via the portal circulation. Depending on the local tissue environment, they
adapt an M1 (pro-inflammatory) or M2 (anti-inflammatory) polarisation. During liver injury, Kupffer
cells are activated to release mediators such as TGF-β and platelet-derived growth factor (PDGF),
which regulate the activation of HSCs into myofibroblasts, promoting hepatic fibrosis [19].
The liver, due to its anatomical location and structure, participates in the induction of tolerance to
food. However, after activation of an immune response and inflammatory processes, for example to a
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neoplasm, hepatic macrophages and HSCs release large amounts of cytokines and adhesion molecules.
These proteins contribute to the activation of endothelial cells, which facilitates the extravasation of
neoplastic cells into the liver. These cells, in context of the tolerant liver environment, can develop into
metastases (Figure 2) [7,9,20,21]. Indeed, metastasis is the result of a complex interaction involving
the extracellular matrix, the tumour, the inflammatory cells and the blood vessels. Inflammatory cells
produce several types of chemokines at the site of inflammation, thus recruiting additional leukocytes,
HSCs and endothelial cells that are overall involved in the homing and proliferation of cancer cells.
Changes in the types and concentrations of these chemokines or in the expression of their receptors
have been implicated in the development of fibrosis and HCC [22,23].
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by  the portal  circulation. Current  evidence  suggests  that  these  cells  are  the principal  effectors of 
fibrogenic PDGF‐ and TGF‐β‐mediated signalling, which activate HSCs and  regulate extracellular 
Figure 2. Crosstalk among mediators of liver injury. In the absence of Wnt ligands, the Wnt/β-catenin
signalling pathway is mostly inactive. During cell regenerative processes and in certain pathological
conditions, the Wnt/β-catenin signal is activated. Wnt/β-catenin signalling controls several processes
such as cell growth, differentiation and polarisation. Chemokines released by Kupffer cells during
liver injury recruit several cell types such as leukocytes, hepatic stellate cells (HSCs) and endothelial
cells to the site of injury. These cells regulate the extracellular VEGF-mediated processing of vascular
permeability and angiogenesis and, through the differentiation of HSCs to myofibroblasts, promote
fibrosis. Kupffer cells become activated when they phagocytise blood-borne pathogens transported
by the portal circulation. Current evidence suggests that these cells are the principal effectors of
fibrogenic PDGF- and TGF-β-mediated signalling, which activate HSCs and regulate extracellular
matrix accumulation. VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor;
TGF-β, transforming growth factor beta.
The structural unit that supports the architecture of each liver lobule is the hepatocyte, which must
be able to regenerate and maintain polarity. Hepatocytes are involved in many vital functions such as
synthesis, metabolism of carbohydrates, protein and lipids, and removal of toxic substances. For these
activities, hepatocytes have three distinct plasma membrane domains separated by tight junctions:
basal, lateral and apical [24]. The basal domain faces the hepatic sinusoids and filters the sinusoidal
blood flow. The apical domain forms the hepatocyte-bile canalicular network that transports bile acids
from blood through hepatocytes into the bile ducts. The lateral membrane domain forms a zonula
occludens that separates the bile duct from the blood, thus forming a blood–bile barrier that restricts
the mixing of blood and bile. Thus, preservation of normal membrane polarity is vital for hepatocyte
functionality, such as apical bile secretion and simultaneous basal secretion of large quantities of serum
proteins into the blood. The main factor involved in the formation and maintenance of hepatocyte
polarisation is the Wnt/β-catenin signalling pathway (Figure 2). Wnt is a secreted glycoprotein that,
by binding its receptor, stabilises β-catenin such that the latter protein cannot be phosphorylated.
β-catenin then accumulates in the cytoplasm and then translocates to the nucleus, where it activates
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the cell polarity signalling that regulates the cytoskeleton responsible for the form and polarity of
hepatocytes [25]. The concentration of Wnt thus regulates hepatocyte metabolic zonation and polarity.
3. The Liver as an Immunological Organ
The liver is a common site of metastasis for many tumours. This reality is due to the organ’s
sinusoidal structure, which permits the extravasation of tumour cells, and also due to its tolerogenic
nature as an organ tasked to metabolise gut-derived microbial products and nutrients. Because of these
functions, the liver environment favours immune tolerance to counterbalance the impact of stress,
which is particularly strong in the liver. Indeed, high concentrations of antigens produced by food
transition and the presence of commensal bacteria in the intestine, which are poured in the hepatic
blood circulation, especially in cases of inflammatory bowel disease, strongly stimulate the immune
system and may cause liver inflammatory [26,27].
The hypothesis that the immune system could play a role in the development of neoplasia has
been a subject of debate for many years. Evidence in support of the liver tolerance ability includes
the observations that immune cells, in particular natural killer (NK) cells, contribute to improved
survival after liver transplantation, and the finding that a decrease in immune defences, due to old age,
immunosuppressive therapy or autoimmune disease, increases the risk of liver metastasis [28–30]. Even
smoking, alcohol abuse and poor nutritional status, which can alter the immune system, increase the
risk of HCC. Furthermore, neoplasms in immunocompromised subjects are generally more aggressive
than in immunocompetent persons. Therefore, a patient’s immunological status has been proposed as
a prognostic marker for HCC [31,32].
The liver contains numerous adaptive and innate immune cells that recognise foreign substances,
recruit leukocytes, and are present to lymphocytes the antigens taken up from the circulation. In
order to be effective, the immune system needs to be activated only against foreign molecules and not
activated against host molecules; to do this, the immune response needs to be continuously controlled.
The control between activating and inhibiting signals from the immune response is what characterises
the liver as an immunologic organ [33]. The liver, through the blood circulation, continuously exchanges
immunological information with body tissues. In particular, it secretes cytokines (e.g., interferon
gamma (IFN-γ) and interleukins (IL) (IL-2, IL-7 and IL-15)) in response to inflammatory signals
mediated by other cytokines, toll-like receptors, tumour necrosis factor alpha (TNF-α). Thus, liver is a
crucial organ for host immunity. This exchange of information is facilitated by the extensive filtering of
blood by the liver. The total blood volume circulate through the liver about 360 times each day and the
liver receiving about 30% of the total blood volume each minute.
The liver harbours several immune cell populations, each with its own specific function and
hepatic location (Figure 3) [34]. Kupffer cells invade the space of Disse. They are in direct contact with
the blood circulation through microvilli that penetrate the endothelium and interact with hepatocytes.
There are two distinct subpopulations of Kupffer cells: an M1 CD68+ subset with phagocytic capacity
and an M2 CD11b+ subset with cytokine-producing capacity [35]. The M1 subset produces high
levels of nitric oxide (NO) and reactive oxygen species (ROS) that kill microorganisms and skew T cell
responses towards a T helper type 1 (TH1) response. The M2 subtype secrets large amounts of IL-10,
which is crucial for the induction of tolerance to hepatocyte antigens, and small amounts of IL-12.
Moreover, the M2 cells express both pro-inflammatory cytokines (TNF-α, IL-1 and IL-6), especially
when exposed to immunocomplexes or bacterial lipopolysaccarides, and anti-inflammatory cytokines
(IL-10 and TGF-β). In addition, Kupffer cells have been shown to cross-present antigens to T cells and
to recruit T helper type 2 (TH2) cells to the liver [36].
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Steatosis  is  an  accumulation  of  triglycerides  in  hepatocytes.  Risk  factors  for  steatosis  (and 
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Figure 3. Schematic of the liver harbouring i s immune cell opulations with differe t fu ctions.
Kupffer cells near or ins de the sinusoids decre une reactions by releasing cytokines; if these
cytokines prom te inflam ation, the Kupffer lls re acting as M1 macrophages; if the cytokines
decrease inflammation and promote tissue repair, the cells are M2 macrophages. Dendritic cells, the
main antigen-presenting cells of the immune system, are mostly present in the subcapsular space. The
capsule is in contact with the viscera and peritoneum, and thus is a barrier for pathogens and neoplastic
cells arriving from these sites. Neutrophils, the most abundant cell type in the blood, accumulate
at sites of injury and release matrix metalloproteinases (MMPs) and reactive oxygen species (ROS),
exacerbating tissue damage. Lymphocytes in the blood and bile are involved in innate and adaptive
immunity and are related in the formation of ectopic germinal centre-like structures in the liver during
certain pathological situations (e.g., hepatitis C virus infection). NK (natural kill r) cells, natural killer
cells; γδ T cells, gamma delta T cells that have a distinctive T cell receptor (TCR) composed of γδ.
Activated Kupffer cells have bee implicat d in hepatocarcinogenesis [35]. During liver injury,
activated Kupffer cells secrete multiple inflammatory cytokines, in particular TNF-α and ROS, which
induce hepatocyte growth and cause DNA damage, respectively. A large number of cells that
accumul e DNA damage can drive carcinogenesis. Furthermore, in liver i jury, activated Kupffer cells
produce igh levels of che okine (e.g. CCL2 and CXCL10) that recruit immune cells (macrophages
and T cells) to the liver, t is process is imp rta t for liver regeneration. According to the response
to mediators in the liver (e.g., inflammatory IFN-γ, lipopolysaccharide or anti-inflammatory IL-4,
IL-10 and IL-13), macrophages give rise to pro-inflammatory M1 macrophages or regulatory M2
macrophages. Polarisation towards the M2 macrophage phenotype is associated with hepatic tissue
repair and suppression of the adaptive immune system, thus allowing HCC to grow and metastasise [37].
During liver injury, Kupffer cells also play an indirect role in liver repair through the activation of HSCs
by cell–cell interactions and the release of cytokines, including macrophage infla matory protein
(MIP)-1, leading to collagen deposition [38]. Wh n the cau e of liver insu t ceases, Kupffer cel s switch
their phenotype towards a reparative function. However, if the insult persists, then fibrosis may
develop and the tissue may degenerate, activating a hepatocarcinomatous process (reviewed in [39]).
The exact role of Kupffer cells in fibrinogenesis and hepatocarcinogenesis remains elusive, but it is
hoped that a better understanding of the functions of different Kupffer cell subsets could help develop
new treatments for liver disease [40]. Research in mice has already shown that Kupffer cells can be
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transplanted from healthy donor animals into animals with experimental liver damage where they
exert beneficial effects [41].
Dendritic cells (DCs) are specialised antigen-presenting cells that play key roles in the initiation
and direction of T cell responses. Antigens circulating in blood and lymph are captured by DCs, and
then loaded DCs migrate through the lymph towards the lymph nodes, where they present the antigen
to T cells. In the liver, DCs are found in the subcapsular space and around vessels such as the central
veins [42]. Their location in the subcapsular space is fundamental to protecting the liver from bacteria,
viruses, toxins and metastasizing neoplastic cells from the peritoneal cavity. Finally, in response to a
hepatic viral infection, DCs induce and sustain CD8+ T cells against infected hepatic cells. Given DCs’
important role in initiating antiviral T cell immune function, the possibility of targeting antigens to
these cells has been proposed as a vaccination strategy against chronic hepatic virus infections [43].
Granulocytes, neutrophils and eosinophils migrate from the blood to the injury site in the liver,
following gradients of chemokines from activated immune cells and of fragments of dead cells
(e.g., pieces of genomic DNA and mitochondrial byproducts) [44]. These cells accumulate in the
microvasculature and then extravasate into the parenchyma by binding to integrin and vascular
adhesion molecules. During extensive endothelial cell damage, they directly extravasate without
the need for these adhesion molecules. At the site of liver injury, they release proteases including
matrix metalloproteinases and generate ROS which exacerbate the tissue damage [45]. In addition to
amplifying tissue injury during the acute phase of inflammation, these cells also clear and repair the
injured area [46].
Lymphocytes are enriched and naturally activated in the liver [47]. Here, most lymphocytes (up to
65%) are NK cells [48]. Recent studies have suggested that NK cells are involved in HCC development
and chronic hepatic viral infection [49,50]. The second most numerous group of lymphocytes in liver
are γδ T cells (15%–25% of all T cells) [51]. These cells have T-cell receptors composed of one γ chain
and one δ chain, which recognise a limited set of antigens such as stress proteins and non-protein
antigens. γδ T cells accumulate in the portal area and bile duct during fibrogenesis, but their role
remains elusive [52]. Finally, the liver contains B cells. During infection, intraportal lymphoid follicles
have a germinal center-like structure, in which activated B cells are surrounded by a follicular DC and
T cell network. The distribution of these B cells and the gene expression patterns in immune cells in
the lymphoid follicles around the portal vein are similar to those seen in lymph nodes, suggesting that
these structures function as germinal centres [53].
4. Role of Liver Damage in Permitting Liver Metastasis
There are several hypotheses regarding the pro-metastatic state of a damaged liver consequent
to cirrhosis, steatosis and nonalchoholic fatty liver disease. Some authors sustain that the altered
hepatic cytoarchitecture, consequent to cirrhosis and steatosis, creates an unfavourable environment
for the development of metastasis [54,55]. Others sustain that these alterations slow the passage of
neoplastic cells through the microcirculation, and enhance cellular-vascular contact and accentuate
microthrombotic phenomena through the expression of adhesion molecules, thereby facilitating
metastasis [56–58]. Moreover, inflammation and activation of HSCs during liver injury create a
microenvironment favourable not only for the development of primary hepatic tumours but also for
the growth of metastases [59]. Neutrophils at an inflammatory site produce numerous molecules
involved in inflammation and DNA damage (e.g., ROS), leading to carcinogenesis [60]. Neutrophils are
also active in remodelling the extracellular matrix, especially the laminin component, which has been
found to trigger cancer cell proliferation [61]. These findings underline the importance of neutrophils
in most sites of tumour recurrence and metastasis, and highlight the well-known link between chronic
inflammation and cancer.
Steatosis is an accumulation of triglycerides in hepatocytes. Risk factors for steatosis (and
steatofibrosis) include metabolic syndrome and hepatitis virus infections. Steatosis is a reversible
phenomenon, but when it persists, it modifies the hepatic cytoarchitecture. These changes in the
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architecture of the liver reduces the flow of blood and blood cells in the liver. Lipid accumulation,
combining with ballooning degeneration, chronic portal inflammation, fibrosis, neoplastic microthrombi
and an imbalance between the production and reduction of free radical fatty acids all contribute to
creating a pro-inflammatory state with altered blood flow. In this setting, a nonalcoholic fatty liver
disease (NAFLD) like steatosis develops into nonalcoholic steatohepatitis (NASH), causing fibrosis
which results in cirrhosis. Traditionally, HCC was thought to develop mostly from cirrhosis. However,
it is now clear that HCC as well as liver metastasis can also develop directly from inflammation without
cirrhosis; this disease evolution is associated with metabolic disorders [62,63]. Several studies in animal
models showed that obesity, dyslipidaemia and hyperglycaemia predispose to the development of
HCC and liver metastases despite the absence of fibrosis, which is mainly present in NASH [64–66].
Thus, an increasingly important role is recognised for NAFLD as a leading cause of end-stage liver
disease, although other genetic and environmental factors may influence the natural history of HCC.
This carcinogenic role is likely due to some characteristics of NAFLD rather than to a fibrosis-induced
alteration of hepatic cytoarchitecture (not yet been established in NAFLD). It may be due to obesity
with low-grade inflammation, causing steatosis, oxidative stress, lipotoxicity and the secretion of
several adipokines, in concert with an insulin-like growth factor signalling [67]. NAFLD in particular, is
characterized by a high hepatic triglyceride and cholesterol content. The excessive lipotoxic cholesterol
content induces nonalcoholic steatohepatitis, which strongly predisposes to HCC.
NASH is a type of NAFLD characterised by steatosis, inflammation and necrosis. If NASH
persists over time, the body’s attempts to repair the damage can lead to fibrosis by the replacement
of hepatocytes with connective tissue. NASH can only be diagnosed by liver biopsy, but it can be
suspected in patients with obesity, insulin resistance or high serum levels of transaminases; it is
associated with a large production of ROS and the risk of HCC [67,68].
Oxidative stress, an essential factor in the pathogenesis of gastrointestinal mucosal diseases, was
found to occur early in chronic liver diseases and in liver inflammatory responses. Consequently, the
extetd of oxidative stress may reflect the degree of liver damage and hence the pro-metastatic
predisposition of the parenchyma [69]. Markers of cell injury caused by oxidative stress are
8-oxo-20-deoxyguanosine (8-oxo-dG; a product of DNA oxidation) and malondialdehyde (from
the peroxidation of polyunsaturated fatty acids in the plasma membrane). Monitoring these markers
in vivo is difficult due to their short half-lives and the balance between oxidative and anti-oxidative
species. Thus, today, there is no consensus on the clinical value of assessing oxidative stress.
5. Impact of Intestinal Microbiota on Liver
The intestinal microbiota consists of a variety of bacteria, viruses and fungi, present in different
amounts, depending on the site within the intestinal tract and the subject’s age, ethnicity and state of
health [70]. The microbiota plays important roles in the development, maturation and functioning of
the immune system [71]. It has been suggested that certain microbiotic compositions and the presence
of systemic inflammation facilitate HCC carcinogenesis, particularly in patients with cirrhosis and
steatosis [72].
The interest in gut microbiota has grown recently with the discovery that it interacts with several
extra-intestinal organs, including those of the cardiovascular system, the kidneys, brain, bone and
especially liver [73]. The composition of the microbiota changes from birth to adulthood under the
influence of both intrinsic and extrinsic factors, such as diet, exercise, infections, and antibiotic therapy
and surgery [74–76]. Several diseases, including obesity, type I diabetes, and the inflammatory bowel
diseases like Crohn’s disease and ulcerative colitis, alter the intestinal microbiota [73].
The liver receives nutrients, toxins and microorganisms via the portal vein from the gut. When
the intestine is inflamed, it is more permeable, so a greater amount of toxins and bacteria can reach
the liver, favouring the development of inflammation in the liver [77–80]. Bile acids produced by
the liver not only facilitate the absorption and elimination of fats in the intestine, but also interact
directly with cellular receptors and bacteria in the intestine. In fact, bile acids and bacteria have
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complementary effects: bile acids limit the pool of bacteria in the intestine through their bacteriostatic
functions, while bacteria reduce the concentration of bile acids by metabolism [81]. Bile acids are
implicated in the aetiology of several diseases, including recurrent infection, inflammatory bowel
disease, metabolic syndrome and several cancers [77], but how the microbiota change the composition
of the bile to cause disease is not clear. Bile acids that do not recycle through the enterohepatic
circulation are transformed by gut bacteria into secondary bile acids that return to the liver in
conjugated forms [82]. The conjugation process makes the bile acids less toxic, more water-soluble, and
capable of protecting against damage from toxic hydrophobic bile acids, which can cause oxidative
stress and cell death. Therefore, alterations in the gut microbiota and their metabolism of bile acids
could cause hepatotoxicity [83,84]. Gut microbiota can exacerbate liver diseases by several mechanisms
(Figure 4): (i) the microorganisms produce prostaglandins that can suppress tumour immunity [85]; (ii)
after an increase in intestinal permeability, bacteria and their metabolites (e.g., lipopolysaccharides
and indoles) translocate to the liver where they induce inflammation and favour the development of
an pro-cancerous milieu [86]; (iii) during high-fat diets, bacteria may alter the bile acid composition,
leading to the accumulation of secondary bile acids in the liver [77]. Given this insight into the
impact of gut microbiota on liver, there is now interest in treating liver disease by manipulating the
microbiota. Dietary interventions being tried include the administration of prebiotics, probiotics or
synbiotics, to reduce the serum levels of triglycerides, cholesterol and lipopolysaccharides, combat
glucose intolerance and metabolic endotoxemia, and prevent the accumulation of secondary bile
acids [85,87,88]. In this context, faecal microbiota transplantation is being explored as a way to optimise
microbiota composition and functionality and ultimately treat liver diseases [89–94].
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Figure 4. The gut–liver axis. The gut microbiot c rbates liver diseases by: (i) the production of
prostaglandins which suppress tumour im unity; (ii) the translocation of bacterial lipopolysaccharides
(LPS) and other metabolites, particularly indoles, to the liver and other organs during states of high
intestinal permeability; and (iii) the alterations of bile acid composition, leading to the accumulation of
secondary bile acids in the liver.
6. Circadian Homeostasis of Liver Metabolism
The circadian rhythm modulates most cellular functions in relation to the light–dark and
temperature cycles caused by rotation of the Earth. The circadian regulation of metabolism also affects
carcinogenesis, including that of the liver, as shown in a study in mice [95]. A chronic alteration of
the circadian rhythm was found to induce spontaneous HCC in wild-ty e mice following NAFLD,
NASH and then fibrosis [95]. A similar cascade of events often takes place in human obesity. Induction
of NAFLD after disruption of the circadian rhythm in mice lea s to an increase in triglycer des and
free fatty acids. This phenomenon is due to a deregulation of fatty acid entry into mitochondria and
to their oxidation to produce energy. As a consequence, high levels of glucose and insulin persist in
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the blood, and glycogen storage in the liver decreases. This is accompanied by the development of
metabolic syndrome (hepatomegaly, bile duct and hepatocyte proliferation, liver inflammation and
fibrosis). In summary, chronic alteration of the circadian rhythm altered liver metabolism and caused
insulin resistance that, by accelerating cytoplasmic glycolysis, promotes lipid synthesis and storage in
liver. However, these metabolic changes occured together with the production of high amounts of
ROS. Because ROS induce liver damage and increase cell division, they favour carcinogenesis. This
effect is called the “Warburg theory of cancer” [96].
According to the Warburg theory of cancer, cancer cells tend to use anaerobic glycolysis (glucose
fermentation) for metabolism instead of the more effective oxidative phosphorylation, because of
insufficient cellular respiration in damaged mitochondria. Oxidative phosphorylation produces up to
36 ATP molecules per molecule of glucose, while anaerobic glycolysis results in just two ATP molecules.
Consequently, neoplastic cells need an increased glucose uptake from the microenvironment and
secrete more lactic acid, the end product of glycolysis. Lactic acid upregulates the expression of
hypoxia-inducible factors (HIFs) and VEGF, which stimulate neo-angiogenesis [97].
The lactate acidification of the microenvironment also has an immunosuppressive action
favouring tumour immune escape [98]. Extracellular acidosis (pH 6.8) was found to inhibit monocyte
differentiation and to promote T cell death and the release of cytokines from cytotoxic T cells [99].
Indeed, activated T cells that accumulate in a tumour site cannot perform glycolysis, which is necessary
for generating energy for daily functions including cytokine release, due to the blockade of their
lactate efflux into the microenvironment as a consequence of an unfavourable ratio between intra- and
extracellular pH values. As a consequence, the cytotoxic immune response is blocked. To resolve this
problem, at least in part, new drugs that regulate the pH and correct the cellular metabolism are now
being developed [100,101].
Circadian rhythm also influences the complex neuronal network and the release of neurohumoural
factors (e.g., cortisol) (Figure 5). It has long been recognised that psychosocial conditions affect the
progression of some cancers [102]. Recently, neuronal mechanisms have been implicated in the regulation
of proliferation and migration of different tumours and metastases, HCC included [103]. Cortisol is a
hormone released into the blood by the adrenal glands under control of the pituitary gland; cortisol release
has a diurnal cycle but it is also released in response to stress and low hypoglycemia. Cortisol induces an
increase in glycemia by stimulating gluconeogenesis in the liver. Cortisol is also generated by adipose
tissue and secreted, together with other hormones, into the blood from where they are taken up by the
liver. Thus, psychologicalstress, particular in obese persons, may result in the accumulation of cortisol in
the liver, where it contributes to liver steatosis and predisposes to HCC [104,105].
Cancers 2019, 11, x  10  of  16 
 
insulin persist in the blood, and glycogen storage in the liver decreases. This is accompanied by the 
development of metabolic  syndrome  (hepatomegaly, bile duct and hepatocyte proliferation,  liver 
inflammation  and  fibrosis).  In  summary,  chronic  alteration  of  the  circadian  rhythm  altered  liver 
metabolism and caused insulin resistance that, by acc lerating cyt plasmic glyc lysis, promot s lipid 




fermentation)  for metabolism  instead of  the more effective oxidative phosphorylation, because of 
insufficient cellular respiration in damaged mitochondria. Oxidative phosphorylation produces up 
to 36 ATP molecules per molecule of glucose, while anaerobic glycolysis  results  in  just  two ATP 
molecules.  Consequently,  neoplastic  cells  need  an  increased  glucose  uptake  from  the 
microenvironment and secrete more lactic acid, the end product of glycolysis. Lactic acid upregulates 
the expression of hypoxia‐i ducible factors (HIFs) a d VEGF, which  timulate neo‐angiogenesis [97].   
The  lactate  acidification  of  the  mic oenvironment  also  has  an  immunosuppressive  acti  
favouring tumour immune escape [98]. Extracellular acidosis (pH 6.8) was found to inhibit monocyte 
differentiation and to promote T cell death and the release of cytokines from cytotoxic T cells [99]. 




resolve  this  problem,  at  least  in  part,  new  drugs  that  regulate  the  pH  and  correct  the  cellular 
metabolism are now being developed [100,101]. 
Circadian  rhythm  also  influences  the  complex  neuronal  network  and  the  r lease  of 











Figure  5.  Possible  causes  of  liver  damage  due  to  circadian  rhythm  alterations,  hypoxia  and 
psychological  stress.  Disruption  of  the  circadian  rhythm  is  a  risk  factor  for  obesity,  metabolic 
disorders  and  HCC.  Hypoxia‐inducible  factors  (HIFs)  control  gene  expression  during  hypoxia, 
enabling cells to survive in a hypoxic environment. HIFs reprogramme the cell’s metabolism towards 
anaerobic  glycolysis  to  increase  energy  through ATP production,  thus  lowering  the pH  value  of 
tissue. Low pH activates the inflammatory program of monocytes, reduces the number and function 
Figure 5. Possible causes of liver damage due to circadian rhythm alterations, hypoxia and psychological
stress. Disruption of the circadian rhythm is a risk factor for obesity, metabolic disorders and HCC.
Hypoxia-inducible factors (HIFs) control gene expression during hypoxia, enabling cells to survive
in a hypoxic environment. HIFs reprogramme the cell’s metabolism towards anaerobic glycolysis to
incre se energy through ATP production, thus lowering the pH value f tissue. Low pH activates
the inflammatory program of monocytes, reduces the number and f nction of T cells, and pr motes
angiogenesis. Chronic psychological stress leads to a cortisol secretory burst, which creates an
immunosuppressive state in the liver.
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7. Conclusions
In recent years, the incidence and development of HCC has changed substantially due to the
introduction of an anti-hepatitis B virus (HBV) vaccine and anti-HCV therapy. However, there has been
no decline in the incidence of HCC associated with other diseases (in particular NAFLD, NASH and
metabolic syndrome). A difference concerning HCC occurring in a background of or without cirrhosis
also is emerging as a reflection of a difference in HCC pathogenesis. The common denominator of HCC
risk among these different diseases, is the development and maintenance of a hepatic inflammatory
state, in response to a viral infection, the accumulation of fat, or irritating molecules that reach
the liver via blood and bile circulations. The fact that this inflammatory or pro-inflammatory state
develops by different mechanisms extends the strategies that can be used at least theoretically, to
reduce the risk of recurrence or metastasis. Of particular interest is the alteration of the cytoarchitecture
and the microcirculation of the liver associated with the development of fibrosis, an increase in
the inflammation of the hepatic microenvironment resulting, in particular, from a greater intestinal
permeability to bacteria and toxins and the lipotoxicity associated with the metabolic syndrome, the
immunosuppressive status occurring in the hepatic environment deriving from social stress, secretion
of adipokines, alteration of the bile acid and the liver metabolism, which favour the engraftment of
HCC. Of noteworthy the same molecular, metabolic and cellular processes, appears to favour also the
development of recurrence and metastasis in the liver. The definition of specific pathways leading
to liver damage offers the possibility of exploring therapeutic or prevention strategies to modulate
the risk of disease recovery. Many of the conditions presented in this review could be modified by
personalised therapeutic plans aimed at a personalised study of nutritional programs, the glycemic and
lipid control, the modification of the intestinal flora and the increase of host immunocompetence, in
addition to the obvious and already obsolete treatment of hepatic viral infections. Moreover, targeted
therapies on distinct metabolic pathways involved in the progression of liver damage are now in
development as reviewed in [106]. Promising drugs being currently studied are, for examples, those
targeting the squalene epoxidase which is involved in the biosynthetic pathway leading to cholesterol.
The squalene epoxidase was found to accumulate in the liver affected by NAFLD, and is associated
with poor survival in patients with HCC [107] and analogues of an enzyme of the classic pathway of
bile acid synthesis from cholesterol, the fibroblast growth factor 19, which are demonstrated to reduce
liver-fat content, inflammation and fibrosis in patients with NASH [108,109].
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